| Iron use (IV or oral), by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 6,054 | 66.3% | 9,117 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 6,396 | 74.7% | 8,552 | |
| DOPPS 3(2007) | 5,718 | 74.5% | 7,672 | |
| AusNZ | DOPPS 2(2002) | 366 | 71.5% | 513 |
| DOPPS 3(2006) | 412 | 78.2% | 527 | |
| DOPPS 3(2007) | 357 | 73.3% | 486 | |
| Belgium | DOPPS 2(2002) | 498 | 92.4% | 538 |
| DOPPS 3(2006) | 460 | 89.9% | 509 | |
| DOPPS 3(2007) | 360 | 84.3% | 420 | |
| Canada | DOPPS 2(2002) | 475 | 79.2% | 601 |
| DOPPS 3(2006) | 435 | 79.9% | 551 | |
| DOPPS 3(2007) | 377 | 84.0% | 445 | |
| France | DOPPS 2(2002) | 346 | 65.8% | 528 |
| DOPPS 3(2006) | 419 | 76.4% | 551 | |
| DOPPS 3(2007) | 454 | 82.4% | 543 | |
| Germany | DOPPS 2(2002) | 452 | 79.1% | 571 |
| DOPPS 3(2006) | 475 | 81.1% | 583 | |
| DOPPS 3(2007) | 494 | 78.9% | 623 | |
| Italy | DOPPS 2(2002) | 303 | 52.5% | 576 |
| DOPPS 3(2006) | 343 | 64.3% | 533 | |
| DOPPS 3(2007) | 346 | 63.8% | 542 | |
| Japan | DOPPS 2(2002) | 699 | 38.5% | 1,805 |
| DOPPS 3(2006) | 1,008 | 54.9% | 1,832 | |
| DOPPS 3(2007) | 1,126 | 60.2% | 1,867 | |
| Spain | DOPPS 2(2002) | 506 | 82.3% | 613 |
| DOPPS 3(2006) | 525 | 78.9% | 666 | |
| DOPPS 3(2007) | 446 | 79.3% | 555 | |
| Sweden | DOPPS 2(2002) | 490 | 89.6% | 547 |
| DOPPS 3(2006) | 468 | 86.5% | 542 | |
| DOPPS 3(2007) | 424 | 82.8% | 511 | |
| UK | DOPPS 2(2002) | 427 | 75.5% | 565 |
| DOPPS 3(2006) | 385 | 86.7% | 445 | |
| DOPPS 3(2007) | 321 | 91.7% | 351 | |
| US | DOPPS 2(2002) | 1,492 | 66.0% | 2,260 |
| DOPPS 3(2006) | 1,466 | 80.3% | 1,813 | |
| DOPPS 3(2007) | 1,013 | 76.7% | 1,329 | |
| Medications reported as prescribed in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.